Every Form 4 that Celldex Therapeutics Inc (CLDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDX filings page.
Celldex Therapeutics reported that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the grant terms, 25% of the option vests on June 25, 2027, with the remaining portion vesting in equal quarterly installments over the following 12 quarters. Following this award, Lawver holds options covering 90,000 shares, reflecting a compensation-related equity incentive rather than an open-market transaction.
Celldex Therapeutics SVP & General Counsel Freddy A. Jimenez received a grant of 93,000 incentive stock options to buy Celldex common stock. The options carry an exercise price of $34.09 per share and were granted under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036, and this award brings his reported derivative holdings in this grant to 93,000 options.
Celldex Therapeutics, Inc. reported that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options to buy common stock.
The options have an exercise price of $34.09 per share, were granted under the company’s 2021 Omnibus Equity Incentive Plan, and represent compensation rather than an open-market purchase.
According to the filing, 25% of the award will vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the options will expire on June 25, 2036 if not exercised.
Celldex Therapeutics, Inc. reported that SVP of Regulatory Affairs Margo Heath-Chiozzi received an incentive stock option grant. The award covers 95,000 options to buy Celldex common stock at an exercise price of $34.09 per share, with 95,000 options held after the transaction.
According to the footnotes, the grant was made under the company’s 2021 Omnibus Equity Incentive Plan. Twenty-five percent of the options vest on June 25, 2027, and the remaining options vest in equal quarterly installments over the following 12 quarters, with the options expiring on June 25, 2036.
Celldex Therapeutics, Inc. reported that its SVP and CFO, Martin Samuel Bates, received an incentive stock option grant covering 93,000 shares of common stock. The option has an exercise price of $34.09 per share and was awarded under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the option expires on June 25, 2036. After this grant, Bates holds 93,000 incentive stock options directly.
Celldex Therapeutics, Inc. reported that SVP of Corporate Affairs & Administration Sarah Cavanaugh received a grant of incentive stock options. She was awarded options covering 95,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.
Following this grant, she holds derivative securities for 95,000 underlying shares. The options have a long-term vesting schedule: 25% vest on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the subsequent 12 quarters, and they expire on June 25, 2036.
Celldex Therapeutics, Inc. reported that senior vice president and chief product development officer Elizabeth Crowley received a grant of options covering 100,000 shares of common stock. These incentive stock options have an exercise price of $34.09 per share and expire on June 25, 2036.
According to the disclosure, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. After this grant, Crowley holds derivative securities representing 100,000 options directly.
Celldex Therapeutics, Inc. granted Senior Vice President and Chief Business Officer Ronald Pepin an incentive stock option covering 20,000 shares of common stock. The option has an exercise price of $34.09 per share and was issued under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The option expires on June 25, 2036, and Pepin holds 20,000 derivative securities following this grant.
Celldex Therapeutics, Inc. Executive VP & Chief Scientific Officer Tibor Keler received an incentive stock option grant covering 115,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the vesting terms, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. After this grant, Keler holds options for 115,000 underlying shares directly.
Celldex Therapeutics, Inc. reported that President and CEO Anthony S. Marucci received a grant of 375,000 Incentive Stock Options to buy Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.
These options start vesting with 25% becoming exercisable on June 25, 2027, and the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.
Celldex Therapeutics, Inc. reported that director Denice Torres received a grant of 26,000 non-qualified stock options to buy Celldex common stock. The options have an exercise price of $34.09 per share, were granted as of June 25, 2026, and expire on June 25, 2036. Following this award, Torres holds 26,000 derivative securities directly.
Jain Rita reported acquisition or exercise transactions in this Form 4 filing.
Celldex Therapeutics director Rita Jain received a grant of 26,000 non-qualified stock options to buy common stock at $34.09 per share.
The options were granted at no cost under the company’s 2021 Omnibus Equity Incentive Plan, are first exercisable on June 25, 2027, and expire on June 25, 2036.
Celldex Therapeutics director Neil Garry Arthur received a compensation-related stock option grant. He was awarded non-qualified options to acquire 26,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan. These options become exercisable starting on June 25, 2027 and expire on June 25, 2036, and this grant represents the full 26,000 derivative shares reported as held following the transaction.
Celldex Therapeutics director Cheryl Cohen received a grant of 26,000 stock options. The non-qualified options give her the right to buy 26,000 shares of Celldex common stock at an exercise price of $34.09 per share. They were awarded under the company’s 2021 Omnibus Equity Incentive Plan.
After this grant, she holds 26,000 derivative securities directly, with the options exercisable starting June 25, 2027 and expiring on June 25, 2036. The filing reports no share sales or open-market purchases, indicating a routine equity compensation award rather than a market trade.
Celldex Therapeutics director Keith L. Brownlie received a grant of 26,000 stock options as part of his compensation. These non-qualified options allow him to buy Celldex common stock at an exercise price of $34.09 per share, under the company’s 2021 Omnibus Equity Incentive Plan.
The options become exercisable starting on June 25, 2027 and expire on June 25, 2036. Following this award, Brownlie is reported as holding 26,000 derivative securities (options) of this type.
Celldex Therapeutics director James J. Marino received a grant of stock options as part of his equity compensation. He was awarded non-qualified options covering 26,000 shares of Common Stock, with an exercise price of $34.09 per share. The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan, carry no upfront cost to Marino, and are exercisable beginning on June 25, 2027. These options are scheduled to expire on June 25, 2036 if not exercised. After this grant, Marino holds options on 26,000 shares according to this filing.
Celldex Therapeutics director Herbert J. Conrad received an option grant for 26,000 shares of common stock. The non-qualified stock option has an exercise price of $34.09 per share and expires on June 25, 2036. This award, granted under the company’s 2021 Omnibus Equity Incentive Plan, brings his reported option holdings to 26,000 derivative shares.
Celldex Therapeutics, Inc. director Harry Jr Penner reported receiving a grant of non-qualified stock options. The award covers 26,000 options to buy Celldex common stock at an exercise price of $34.09 per share, expiring on June 25, 2036. The options, issued at no cost to the director, were granted under the company’s 2021 Omnibus Equity Incentive Plan and leave him holding 26,000 derivative securities following the transaction. This is a compensation-related grant rather than an open-market share purchase or sale.
Celldex Therapeutics senior executive reports stock option exercises. A company officer serving as Senior Vice President and Chief Business Officer filed a Form 4 covering two option exercises in Celldex Therapeutics, Inc. common stock on 12/15/2025. The reporting person acquired 8,333 shares at an exercise price of $9.0165 per share and 11,000 shares at an exercise price of $2.78 per share through the exercise of incentive stock options.
Following these transactions, the officer beneficially owns 20,097 shares of Celldex common stock directly, which includes 764 shares acquired under the company’s 2004 Employee Stock Purchase Plan. After the exercises, one option grant for 8,333 shares expiring on 06/13/2028 remains partially outstanding with 5,000 derivative securities beneficially owned, while a second option grant for 11,000 shares expiring on 06/19/2029 has been fully exercised.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.
Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.
Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of $22.67 per share. The options expire on 11/10/2035.
The filing states 25% of the award vests on 11/10/2026, with the remainder vesting in equal quarterly installments over the next 12 quarters. Following the grant, 100,000 derivative securities are listed as beneficially owned in direct form.